Key Players: Thermo Fisher, Danaher, and Agilent

Introduction

Three companies dominate the life sciences tools landscape, each with a distinctive strategic approach. Understanding their models is essential for healthcare bankers working on tools-sector transactions because these three are the primary strategic acquirers, and any sell-side mandate in the space will likely involve positioning the target relative to their portfolios.

Thermo Fisher is the largest life sciences tools company in the world, with annual revenue of approximately $43 billion across four segments: Life Sciences Solutions (instruments, reagents, consumables), Analytical Instruments (mass spectrometry, chromatography), Specialty Diagnostics, and Laboratory Products & Biopharma Services (including the PPD CRO business acquired for $17.4 billion).

Thermo Fisher's "Customer Value" M&A Strategy

Thermo Fisher's acquisition approach centers on becoming a one-stop-shop for laboratory needs. The strategic logic is that a customer who buys instruments, consumables, reagents, services, and CRO support from a single vendor creates cross-selling opportunities and deeper lock-in. Major acquisitions include Life Technologies ($13.6B, genomics and cell biology), Patheon ($7.2B, CDMO services), and PPD ($17.4B, CRO services). The breadth of the portfolio means Thermo Fisher participates in virtually every step of the drug development and manufacturing process.

Thermo Fisher's scale gives it unmatched distribution: its e-commerce platform and direct sales force reach more than 400,000 customers globally. For mid-market tools companies being acquired, Thermo Fisher's distribution network is the primary revenue synergy source, as smaller companies can rarely build this level of global commercial reach independently.

Danaher operates a fundamentally different model built around the Danaher Business System (DBS), a continuous improvement methodology derived from the Toyota Production System. Danaher acquires companies, applies DBS to improve margins and growth, and compounds value over long hold periods.

After spinning off its environmental and dental businesses (Veralto and Envista), Danaher is now a pure-play life sciences and diagnostics company, with key franchises including Cytiva (bioprocessing), Beckman Coulter (diagnostics and life sciences), Pall (filtration), and Leica Microsystems (microscopy). The bioprocessing business through Cytiva gives Danaher direct exposure to biologics CDMO-adjacent services, supplying the bioreactors, filtration systems, and chromatography resins that biologics manufacturers use.

Agilent is smaller and more focused than Thermo Fisher or Danaher, concentrating on analytical instruments (liquid chromatography, gas chromatography, mass spectrometry) and the consumables and services that support them. Annual revenue is approximately $6.5 billion, with the CrossLab division (consumables, services, software) generating the highest-margin, most recurring portion.

Agilent's CrossLab strategy is a deliberate effort to shift the revenue mix toward recurring streams. CrossLab provides consumable columns, sample preparation products, service contracts, compliance software, and lab informatics. The division's growth rate consistently exceeds the instrument business because every instrument sold feeds the CrossLab installed base, generating spec-in protected consumable revenue for years.

The next article covers the post-COVID destocking cycle and what it revealed about the cyclicality risks even in high-recurring-revenue tools businesses.